Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2022 16:00 ET | Source: Virogin Biotech

Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors

VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study...
November 15, 2022 07:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update

– Company continues to execute and is well-positioned to achieve multiple near-term clinical and regulatory value-driving milestones – Cash position expected to fund operations through end of 2023 ...
November 14, 2022 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update

Initiation of Phase 1/2a endometrial cancer trial expected in 1Q23; preliminary data expected 4Q23 Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., Nov. 14, 2022 (GLOBE...
November 14, 2022 07:00 ET | Source: PDS Biotechnology Corporation

PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial

In the trial studying the combination of PDS0101 with standard-of-care chemoradiotherapy: 100% (9/9) showed clinical response (>60% tumor shrinkage at mid-point evaluation)89% (8/9) had no...
November 14, 2022 07:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer

– Data selected for poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting – Treatment was well tolerated, with promising clinical activity of pathologic complete...
November 14, 2022 03:51 ET | Source: Fortune Business Insights

Cosmetic Surgery Market Size (2021-2028) Worth USD 58.78 Billion, 3.6% CAGR

Pune, India, Nov. 14, 2022 (GLOBE NEWSWIRE) -- The global Cosmetic Surgery Market size was accounted at USD 44.55 billion in 2020. The market is projected to grow from USD 46.02 billion in 2021 to...
November 11, 2022 11:13 ET | Source: Intermountain Healthcare

Intermountain Healthcare Bringing New Artificial Intelligence Technology to Heber Valley, Wasatch Back, & Other Utah Communities to Fight Colon Cancer

Salt Lake City, UT, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Intermountain Healthcare is the first health system in Utah to use a new tool that utilizes artificial intelligence to aid doctors in detecting...
November 11, 2022 10:12 ET | Source: ImCheck Therapeutics SAS

ImCheck Presents Initial Patient Data from the EVICTION-2 Clinical Trial at SITC Annual Meeting

Low-dose ICT01 plus low-dose IL-2 safely and significantly increase the number of activated γ9δ2 T cells, CD8 T cells, and Natural Killer cells in patients with solid tumors Marseille, France,...
November 10, 2022 21:00 ET | Source: Predicine

Predicine to Introduce PredicineCOMPLETE™, its Genome-Wide Liquid Biopsy Solution, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

SILICON VALLEY, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, announces the introduction of PredicineCOMPLETE™, the organization’s most comprehensive...
November 10, 2022 09:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Poster Spotlights CD2 Pathway as a Differentiated T Cell Costimulation Approach for the Treatment of Solid and Hematological Malignancies Modular Platform Being Leveraged to Advance Broad Pipeline of...